% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • wedgemahalo wedgemahalo May 10, 2013 1:17 PM Flag

    Compare to ALXN

    No comparison is perfect, but given some comparisons to Celgene and some to Dendreon - I was compelled to compare to the benchmark company I am using in trying to value PCYC. I compare it to ALXN - a single product company with some rare disease products in development. Currently ALXN market cap is $20 billion and their current product (Soliris has roughly $1billion in annual sales, but growing). PCYC has ending approval for Ibrutinib with three indications. They will have $500 million cash in the bank at the end of the year (yes - $500MM). Payments due from JNJ, Ibrutinib easily is a billion dollar product (and very likely approval soon given breakthrough status with FDA). Currently valued at $5.5 billion. It seems that the only risk is Ibrutinib not being approved, as sales for it will take off right away and it is not a DNDN issue of product just being so disappointing in terms of sales. I see big moves this year with ASCO and approval coming soon....

257.100.00(0.00%)Apr 23 3:59 PMEDT